Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald, Germany.
Sci Rep. 2020 Jan 30;10(1):1487. doi: 10.1038/s41598-020-58430-8.
Obesity is one of the major risk factor for cardiovascular and metabolic diseases. A disproportional accumulation of fat at visceral (VAT) compared to subcutaneous sites (SAT) has been suspected as a key detrimental event. We used non-targeted metabolomics profiling to reveal metabolic pathways associated with higher VAT or SAT amount among subjects free of metabolic diseases to identify possible contributing metabolic pathways. The study population comprised 491 subjects [mean (standard deviation): age 44.6 yrs (13.0), body mass index 25.4 kg/m² (3.6), 60.1% females] without diabetes, hypertension, dyslipidemia, the metabolic syndrome or impaired renal function. We associated MRI-derived fat amounts with mass spectrometry-derived metabolites in plasma and urine using linear regression models adjusting for major confounders. We tested for sex-specific effects using interactions terms and performed sensitivity analyses for the influence of insulin resistance on the results. VAT and SAT were significantly associated with 155 (101 urine) and 49 (29 urine) metabolites, respectively, of which 45 (27 urine) were common to both. Major metabolic pathways were branched-chain amino acid metabolism (partially independent of insulin resistance), surrogate markers of oxidative stress and gut microbial diversity, and cortisol metabolism. We observed a novel positive association between VAT and plasma levels of the potential pharmacological agent piperine. Sex-specific effects were only a few, e.g. the female-specific association between VAT and O-methylascorbate. In brief, higher VAT was associated with an unfavorable metabolite profile in a sample of healthy, mostly non-obese individuals from the general population and only few sex-specific associations became apparent.
肥胖是心血管疾病和代谢疾病的主要危险因素之一。内脏脂肪(VAT)与皮下脂肪(SAT)不成比例的积累被怀疑是一个关键的有害事件。我们使用非靶向代谢组学分析来揭示与代谢疾病患者中 VAT 或 SAT 量较高相关的代谢途径,以确定可能的代谢途径。该研究人群包括 491 名无糖尿病、高血压、血脂异常、代谢综合征或肾功能不全的受试者[平均(标准差):年龄 44.6 岁(13.0),体重指数 25.4kg/m²(3.6),60.1%为女性]。我们使用线性回归模型将 MRI 衍生的脂肪量与血浆和尿液中的质谱衍生代谢物相关联,调整了主要混杂因素。我们使用交互项测试了性别特异性效应,并进行了敏感性分析,以检验胰岛素抵抗对结果的影响。VAT 和 SAT 分别与 155(101 个尿液)和 49(29 个尿液)个代谢物显著相关,其中 45(27 个尿液)个代谢物是两者共有的。主要代谢途径包括支链氨基酸代谢(部分独立于胰岛素抵抗)、氧化应激和肠道微生物多样性的替代标志物,以及皮质醇代谢。我们观察到 VAT 与潜在药物哌啶之间存在新的正相关关系。性别特异性效应很少,例如女性 VAT 与 O-甲基抗坏血酸之间的特异性关联。总之,在一般人群中健康、主要非肥胖个体的样本中,较高的 VAT 与不利的代谢物谱相关,只有少数性别特异性关联变得明显。